Immunotherapy based on the blockade of checkpoints such as PD-1/PD-L1 has revolutionized the treatment of certain cancers, such as melanoma, non-small-cell lung cancer, bladder cancer, and kidney cancer [23]. This evidence concerns the gene CD274 and urinary bladder carcinoma.